# UNITED STATES PATENT US 6,630,507 B1: A Comprehensive Analysis of Federal Hypocrisy
View Full URL https://grok.com/share/c2hhcmQtMg_2796569f-c70f-46fe-bd98-4f0d957c5c43
👮 Age Verification Exploit & Content Disclaimer | (Warning to Wix Website Owners, and Visitors URL# vi5uuw)
BFREEDINDEED.NET MINISTRIES
A NOTE ABOUT OUR STUDIES | URL# pikmieh
━━━━━━━━━━━━━━━━
## The 67 Cannabis Patents, Schedule I Contradiction, & the Suppression of Natural Medicine
(Why many of our studies are now password protected)
## EXECUTIVE SUMMARY URL# 4f0d957c5c43
The historical record of United States intellectual property reveals a continuous, expansive, and federally recognized engagement with cannabis and its constituent compounds. Spanning from the isolation of cannabidiol in 1942 to complex biosynthesis methods patented in 2026, this activity demonstrates a deep, long-standing scientific acknowledgment of the plant's therapeutic potential. However, this record stands in stark contrast to the federal legal classification of cannabis as a Schedule I drug under the Controlled Substances Act—a designation that asserts "no accepted medical use."
This document provides a comprehensive chronological catalog of 67 U.S. cannabis-related patents, analyzing the data to expose a fundamental contradiction: while the U.S. government has actively patented and promoted cannabinoid-based pharmaceuticals, the natural, whole-plant source of these compounds remains prohibited. This analysis underscores the urgent need for policy reform grounded in scientific evidence rather than historical prohibition.
## PART ONE: THE HISTORICAL RECORD
### 1.1 Complete Chronological Patent List (1942-2026)
The U.S. patent record for cannabis and cannabinoids is not a recent phenomenon; it is an eight-decade legacy of federal scientific and commercial activity. This catalog, compiled from Google Patents and Lens.org, represents 67 granted patents that illustrate the evolution of this field from basic chemistry to advanced medical applications.
Linked 67-Patent Master List URL https://chat.deepseek.com/share/6wzfv3nljca1fpt1ui
-
US 2,304,669 (1942) — Isolation of cannabidiol — Extraction/Isolation
-
The patent describes the isolation of substantially pure cannabidiol from hemp red oil. Google Patents identifies Roger Adams as the inventor and gives a publication date of December 8, 1942.
-
US 3,734,930 (1973) — Direct synthesis of trans-tetrahydrocannabinol — Synthetic
-
The patent describes a stereospecific synthesis of Δ⁹-THC from olivetol and carene oxide.
-
US 3,897,306 (1975) — 7-Hydroxy-delta-8-tetrahydrocannabinols and microbiological production
-
US 4,179,517 (1979) — Novel tetrahydrocannabinol type compounds
-
US 4,189,491 (1980) — Tetrahydrocannabinol in a method of treating glaucoma
-
This is a particularly important historical medical patent. It describes the use of THC in treating glaucoma and discusses its administration to glaucoma patients.
-
US 4,279,824 (1981) — Method and apparatus for processing herbaceous plant materials
-
US 4,438,207 (1984) — Radioimmunoassay for cannabinoids
-
US 4,876,276 (1989) — (3S-4S)-7-hydroxy-delta-6-tetrahydrocannabinols
-
US 5,036,014 (1991) — Deuterated cannabinoids as standards for analysis
-
US 5,227,537 (1993) — Production of 6,12-dihydro-6-hydroxy-CBD for trans-delta-9-THC
-
US 5,292,899 (1994) — Synthesis of 11-nor-delta-9-THC-9-carboxylic acid
-
US 5,389,375 (1995) — Stable suppository formulations for delta-9-THC bioavailability
-
US 5,939,429 (1999) — Cardiovascular uses of cannabinoid compounds
-
US 6,403,126 (2002) — Cannabinoid extraction method
-
US 6,630,507 (2003) — Cannabinoids as antioxidants and neuroprotectants — KEY PATENT
-
This is the especially significant U.S. Department of Health and Human Services patent. It concerns cannabinoids as antioxidants and neuroprotectants, including applications involving neurological and neurodegenerative diseases. Google Patents identifies HHS as the original assignee and Aidan J. Hampson, Julius Axelrod, and Maurizio Grimaldi as inventors.
-
US 7,037,910 (2006) — Azabicyclic heterocycles as cannabinoid receptor modulators
-
US 7,279,500 (2007) — Sulfonamide cannabinoid agonists and antagonists
-
US 7,449,589 (2008) — Process for purifying (-)-delta-9-trans-THC
-
US 7,592,468 (2009) — Production of delta-9-tetrahydrocannabinol
-
US 7,622,140 (2009) — Processes and apparatus for extraction of active substances
-
US 8,106,244 (2012) — Process for production of delta-9-tetrahydrocannabinol
-
US 8,445,034 (2013) — Systems and methods for producing organic cannabis tincture
-
US 8,530,679 (2013) — Delta-9-tetrahydrocannabinol processing
-
US 8,628,796 (2014) — Room-temperature stable dronabinol formulations
-
US 8,808,734 (2014) — Cannabinoid formulations
-
US 8,884,100 (2014) — Aromatic prenyltransferase from Cannabis — Biosynthesis
-
This is a particularly interesting patent. It concerns a Cannabis sativa aromatic prenyltransferase, CsPT1, involved in cannabinoid biosynthesis and describes genetic mechanisms capable of increasing or decreasing cannabinoid production.
-
US 8,895,078 (2014) — Method for producing an extract from Cannabis plant matter containing THC and CBD
-
The patent concerns producing extracts containing THC and CBD from Cannabis plant material, including CO₂ extraction.
-
US 8,846,409 (2014) — Methods of preparing cannabinoids from plant material
-
The patent concerns the preparation of substantially pure cannabinoids from plant material.
-
US 9,034,395 (2015) — Processes and apparatus for extraction of active substances
-
US 9,066,910 (2015) — Methods and compositions of cannabis extracts
-
US 9,066,920 (2015) — Use of phyto-cannabinoids in treatment of epilepsy
-
US 9,435,817 (2016) — Detection of synthetic cannabinoids
-
US 9,474,726 (2016) — Use of cannabinoids in treatment of epilepsy
-
US 9,730,911 (2017) — Cannabis extracts and methods of preparing and using same
-
US 10,189,762 (2019) — Process for purification and separation of cannabinoids
-
US 10,296,714 (2019) — Method and system for medical cannabinoid treatment
-
US 10,406,453 (2019) — Cannabinoid extraction process using brine
-
US 10,413,843 (2019) — Cannabinoid extraction and distillation
-
US 10,413,845 (2019) — Processes for solvent extraction of cannabinoids and terpenes
-
US 10,450,251 (2019) — Process for preparation of 3-substituted cannabinoid compounds
-
US 10,538,790 (2020) — Bioenzymatic synthesis of THC-v, CBV and CBN
-
US 10,568,865 (2020) — Water-soluble compositions comprising purified cannabinoids
-
US 10,647,691 (2020) — Method for purifying cannabinoid compounds
-
US 10,669,248 (2020) — Methods to chemically modify cannabinoids
-
US 10,851,038 (2020) — Ultrasonic cannabinoid extraction using non-flammable co-solvent
-
US 10,941,131 (2021) — Conversion of CBD or delta-9-THCA to delta-8 THC
-
US 11,000,486 (2021) — Combination of cannabinoids in treatment of leukemia
-
US 11,117,852 (2021) — Isolation of pure cannabinoids from Cannabis
-
US 11,274,320 (2022) — Biosynthesis of cannabinoids and cannabinoid precursors
-
US 11,364,505 (2022) — Powderized cannabis and uses thereof
-
US 11,426,362 (2022) — Oral cannabinoid formulations
-
US 11,472,786 (2022) — Methods for converting THC-rich mixtures into CBN-rich cannabinoids
-
US 11,679,087 (2023) — Use of cannabinoids in treatment of Angelman syndrome
-
US 11,766,628 (2023) — Purification and extraction of cannabinoids
-
US 11,844,819 (2023) — Oil extract of cannabis and method for obtaining
-
US 11,903,920 (2024) — Cannabinoid formulation: production method and use
-
US 12,018,301 (2024) — Recombinant olivetolic acid cyclase polypeptides
-
US 12,083,078 (2024) — Parenteral cannabinoid formulations and uses thereof
-
US 12,264,143 (2025) — Synthesis of cannabinoids and cannabinoid precursors
-
US 12,268,142 (2025) — Cannabis variety NWG 4113
-
US 12,364,670 (2025) — Cannabidiol-type cannabinoid compound
-
US 12,383,512 (2025) — Cannabidiol-type cannabinoid compound
-
US 12,396,963 (2025) — Cannabidiol-type cannabinoid compound
-
US 12,403,114 (2025) — Cannabinoid acid ester compositions and uses thereof
-
US 12,472,219 (2025) — Encapsulated cannabinoid formulations for transdermal delivery
-
US 12,496,271 (2025) — Oral cannabinoid formulations
-
US 12,539,472 (2026) — Method of preparing cannabinoids
-
This is a particularly current example: the patent was granted February 3, 2026, and concerns producing stable, substantially pure cannabinoids through processes including decarboxylation, extraction, winterization, and crystallization.
### 1.2 Synthetic Cannabinoid Patents (Linked 25 of 67) URL https://chat.deepseek.com/share/romd0z8c9krr9o06yx
The following patents relate to chemical synthesis, synthetic cannabinoid compounds or analogs, cannabinoid conversion, purification, processing, or other technologies involving chemically produced cannabinoids. Each patent number below links directly to its Google Patents record, allowing the reader to examine the original title, abstract, description, claims, inventors, assignee, priority dates, and legal history.
-
US 3,734,930 (1973) — Direct synthesis of trans-tetrahydrocannabinol
US 3,734,930 — Google Patents
This patent specifically concerns the direct synthesis of trans-Δ⁹-tetrahydrocannabinol from olivetol and carene oxide. It was published May 22, 1973. -
US 3,897,306 (1975) — 7-Hydroxy-delta-8-tetrahydrocannabinols and microbiological production
US 3,897,306 — Google Patents -
US 4,179,517 (1979) — Novel tetrahydrocannabinol type compounds
US 4,179,517 — Google Patents -
US 4,876,276 (1989) — (3S-4S)-7-hydroxy-delta-6-tetrahydrocannabinols
US 4,876,276 — Google Patents
The patent claims specific (3S,4S) compounds and pharmaceutical compositions having analgesic, antiemetic, or antiglaucoma activity. -
US 5,036,014 (1991) — Deuterated cannabinoids as standards for analysis
US 5,036,014 — Google Patents
The patent concerns deuterated cannabinoids used as analytical standards for THC and its metabolites in biological fluids. -
US 5,227,537 (1993) — Method for production of 6,12-dihydro-6-hydroxy-CBD for trans-delta-9-THC
US 5,227,537 — Google Patents
The patent describes the production of 6,12-dihydro-6-hydroxy-cannabidiol and its use in producing trans-Δ⁹-THC. -
US 5,292,899 (1994) — Synthesis of 11-nor-delta-9-THC-9-carboxylic acid glucuronide
US 5,292,899 — Google Patents
Important correction: The actual Google Patents title is "Synthesis of 11-nor-Δ-9-tetrahydrocannabinol-9-carboxylic acid glucuronide." This is more specifically a synthesized THC metabolite/derivative than simply "synthesis of 11-nor-delta-9-THC-9-carboxylic acid." -
US 7,037,910 (2006) — Azabicyclic heterocycles as cannabinoid receptor modulators
US 7,037,910 — Google Patents -
US 7,279,500 (2007) — Sulfonamide cannabinoid agonists and antagonists
US 7,279,500 — Google Patents
The patent concerns sulfonamide compounds functioning as cannabinoid receptor agonists or antagonists. Its record also documents the U.S. patent family and cited cannabinoid literature. -
US 7,449,589 (2008) — Process for purifying (-)-delta-9-trans-THC
US 7,449,589 — Google Patents
This patent concerns purification of (-)-Δ⁹-trans-THC, including chromatographic processes. -
US 7,592,468 (2009) — Production of delta-9-tetrahydrocannabinol
US 7,592,468 — Google Patents
The patent record includes related continuation applications concerning the production of Δ⁹-THC. -
US 8,106,244 (2012) — Process for production of delta-9-tetrahydrocannabinol
US 8,106,244 — Google Patents
The claims describe a chemical process involving intermediate compounds and a carbonate base to produce the resulting cannabinoid compound. -
US 8,530,679 (2013) — Delta-9-tetrahydrocannabinol processing
US 8,530,679 — Google Patents
The patent concerns processing Δ⁹-THC, including solvent-based processing. Google Patents currently lists the patent as active with an adjusted expiration date in 2030. -
US 8,808,734 (2014) — Cannabinoid formulations
US 8,808,734 — Google Patents
The patent describes cannabinoid and cannabinoid-analog formulations, including micelle and liposome delivery systems.
Classification note: This is better described as a formulation/cannabinoid-analog patent rather than a pure synthetic-cannabinoid synthesis patent. -
US 10,450,251 (2019) — Process for preparation of 3-substituted cannabinoid compounds
US 10,450,251 — Google Patents
The patent specifically concerns processes for preparing 3-substituted cannabinoid compounds. -
US 10,538,790 (2020) — Bioenzymatic synthesis of THC-v, CBV and CBN
US 10,538,790 — Google Patents
This belongs particularly well in this section because it concerns biosynthetic/enzymatic production of cannabinoid compounds, including THC-v, CBV, and CBN. -
US 10,669,248 (2020) — Methods to chemically modify cannabinoids
US 10,669,248 — Google Patents
This patent concerns the chemical modification of cannabinoid structures. -
US 10,941,131 (2021) — Conversion of CBD or delta-9-THCA to delta-8 THC
US 10,941,131 — Google Patents
This is particularly relevant to discussions of chemical conversion of cannabinoids, as the patent concerns the conversion of CBD or Δ⁹-THCA into Δ⁸-THC. -
US 11,472,786 (2022) — Methods for converting THC-rich mixtures into CBN-rich cannabinoids
US 11,472,786 — Google Patents
The patent concerns chemical conversion processes that transform THC-rich cannabinoid mixtures into CBN-rich products. -
US 12,264,143 (2025) — Synthesis of cannabinoids and cannabinoid precursors
US 12,264,143 — Google Patents
This is one of the newest patents in the collection and directly concerns the synthesis of cannabinoids and cannabinoid precursors. -
US 12,364,670 (2025) — Cannabidiol-type cannabinoid compound
US 12,364,670 — Google Patents -
US 12,383,512 (2025) — Cannabidiol-type cannabinoid compound
US 12,383,512 — Google Patents -
US 12,396,963 (2025) — Cannabidiol-type cannabinoid compound
US 12,396,963 — Google Patents -
US 12,403,114 (2025) — Cannabinoid acid ester compositions and uses thereof
US 12,403,114 — Google Patents
This patent belongs in the synthetic/chemical-derivative portion of the collection because it concerns cannabinoid acid ester compositions and their uses. -
US 12,539,472 (2026) — Method of preparing cannabinoids
US 12,539,472 — Google Patents
This is the newest patent in this 25-patent subset. It concerns methods for preparing cannabinoids and is particularly useful for demonstrating that cannabinoid-processing and cannabinoid-production patent activity continued into 2026.
### 1.3 What This Record Demonstrates
The historical record is considerably broader than a simple count of the references cited by U.S. Patent 6,630,507. Beginning with the 1942 cannabidiol-isolation patent, the U.S. record encompasses at least the following major areas:
- Cannabidiol isolation and extraction
- Direct synthesis of THC (beginning 1973)
- THC and cannabinoid chemistry
- Cannabinoid analogs and synthetic cannabinoids
- Cannabinoid receptor agonists and antagonists
- Cannabinoid detection and analytical standards
- Glaucoma treatment
- Cardiovascular applications
- Neuroprotection and antioxidant applications
- Cannabis extraction and purification
- Cannabis tinctures
- Cannabinoid formulations
- Epilepsy treatment
- Cancer-related cannabinoid research
- Biosynthetic production of cannabinoids
- Chemical modification of cannabinoids
- Delta-8 THC production
- CBN production
- Transdermal cannabinoid delivery
- Parenteral cannabinoid formulations
- Cannabis plant varieties
This progression demonstrates that federal intellectual-property activity involving cannabis and cannabinoids did not suddenly appear in the modern legalization era. It extends across more than eight decades, from 1942 through 2026.
## PART TWO: THE CORE CONTRADICTION
### 2.1 U.S. Patent 6,630,507 and the Schedule I Paradox
In 2003, the **U.S. Department of Health and Human Services** was granted U.S. Patent No. 6,630,507 for the use of cannabinoids as antioxidants and neuroprotectants. This official federal recognition acknowledges that these compounds are beneficial in treating a range of conditions, including Alzheimer's disease, Parkinson's disease, stroke, and other neurodegenerative pathologies.
**The Paradox:**
- **Federal Patent:** Acknowledges therapeutic efficacy and medical utility.
- **Federal Law:** Classifies the same plant as Schedule I, a category reserved for substances with "no accepted medical use."
This is not an isolated incident. It represents a systemic contradiction in which:
- Whole-plant medicine remains federally prohibited.
- Isolated or synthetic compounds are patented, commercialized, and sold as pharmaceuticals.
- Natural extracts face criminalization, while their pharmaceutical derivatives receive patent protection and market exclusivity.
The United States Patent and Trademark Office has issued hundreds of cannabis-related patents over the past several decades, with thousands of related applications filed. These patents cover cannabinoid compositions (THC, CBD, CBG, CBC and analogs), neuroprotective and antioxidant applications, anti-inflammatory formulations, synthetic cannabinoid analogs, extraction and purification methods, drug delivery systems, cannabis plant genetics and cultivars, and pharmaceutical cannabinoid isolates.
Federal agencies themselves have held or funded cannabinoid patents—including the 2003 patent granted to the U.S. Department of Health and Human Services. This demonstrates a long-standing scientific acknowledgment of cannabinoid pharmacology, even during decades in which cannabis remained classified under Schedule I as having "no accepted medical use."
The contradiction is therefore not limited to a single patent. It reflects a broader pattern of ongoing federal cannabinoid research, government-recognized therapeutic potential, commercial pharmaceutical development, and continued prohibition of the whole plant.
### 2.2 Government and Pharmaceutical Cannabinoid Medicines
Despite claims of "no accepted medical use," a significant body of cannabinoid-based research, patents, and commercial products has been developed, primarily by governments and pharmaceutical corporations, since the 1940s. This creates a dynamic where synthetic or isolated compounds are promoted while the natural whole plant remains illegal.
**FDA-Approved Synthetic and Isolated Cannabinoids (U.S.):**
- **Marinol (Dronabinol)** – Synthetic THC (FDA approved 1985)
- **Syndros** – Synthetic THC (FDA approved 2016)
- **Cesamet (Nabilone)** – Synthetic THC analog (FDA approved 1985)
- **Epidiolex** – Purified plant-derived CBD (FDA approved 2018)
**Internationally Approved or Government-Backed Cannabinoid Medicines:**
- **Sativex (Nabiximols)** – THC:CBD botanical extract (UK, EU, Canada)
- **Bedrocan Medical Cannabis** – Standardized government-regulated cannabis (Netherlands)
- **Tilray Oral Solutions** – Government-approved medical cannabis extracts
- **Cannador** – Standardized THC/CBD capsule (Germany)
**Early Government and Military Research (1940s-1970s):**
- Cannabinol (CBN) – studied by U.S. Army and NIH researchers for sedation and pain relief
- Delta-9-THC (isolated) – synthesized and studied following WWII pharmacological programs
- Delta-8-THC – government-researched isomer, later commercialized
- Nabilone (early synthesis) – cannabinoid analogs explored for nausea
- Levonantradol – U.S. Army-funded synthetic cannabinoid for pain (1970s)
**Investigational, Suppressed, or Abandoned Cannabinoid Drugs:**
- Dexanabinol (HU-211) – neuroprotectant studied for stroke and TBI
- Rimonabant – CB1 antagonist (withdrawn despite metabolic benefits)
- Ajulemic Acid (CT-3) – synthetic THC metabolite (anti-inflammatory)
- O-1602 – cannabinoid-like compound targeting inflammation
- HU-210 – potent synthetic cannabinoid (Israeli government research)
**Modern Pharma and Government Cannabinoid Programs:**
- GW Pharmaceuticals cannabinoid isolates (pre-acquisition by Jazz Pharma)
- NIH-funded CBD analogs for addiction and anxiety
- DEA-registered cannabinoid research compounds
- CBG/CBC pharmaceutical isolates currently in development pipelines
## PART THREE: THE DELTA-8 FALSE ALTERNATIVE
### 3.1 What Is Delta-8 THC?
Delta-8-tetrahydrocannabinol (Delta-8 THC) is a minor cannabinoid found naturally in cannabis in small quantities. It is chemically similar to Delta-9 THC (the primary psychoactive compound in cannabis) but with a slightly different molecular structure.
**The Legal Loophole:**
- Delta-8 is often derived from hemp-derived CBD
- Under the 2018 Farm Bill, hemp derivatives are federally legal
- Delta-8 products exploit a loophole in the law
- They are widely available online and in stores, including to minors
### 3.2 Safety Concerns
- Inconsistent dosing – Products vary widely in potency
- Contamination – Many products contain heavy metals, pesticides, or residual solvents
- Lack of regulation – No federal oversight of manufacturing
- Synthetic conversion – Often chemically converted from CBD using potentially harmful reagents
- Adulteration – Some products contain unknown or dangerous compounds
- Youth appeal – Marketed with candy-like packaging and flavors
### 3.3 The "False Alternative" Problem
While natural, whole-plant cannabis remains federally restricted, synthetic derivatives are promoted:
**Delta-8 THC vs. Whole-Plant Cannabis:**
**Legal status:**
- Delta-8: Federally "legal" (loophole)
- Whole-plant cannabis: Federally illegal (Schedule I)
**Regulation:**
- Delta-8: Minimal
- Whole-plant cannabis: None (federally)
**Safety testing:**
- Delta-8: Rarely
- Whole-plant cannabis: Varies by state
**Consumer protection:**
- Delta-8: Very low
- Whole-plant cannabis: Moderate (in legal states)
**Accessibility to youth:**
- Delta-8: High
- Whole-plant cannabis: Low
**Entourage effect:**
- Delta-8: Limited (isolated compound)
- Whole-plant cannabis: Full spectrum
**The Irony:** A less safe product (Delta-8) is legal, while a more studied product (whole-plant cannabis) remains illegal. This creates a false choice between dangerous and illegal products—pushing consumers toward less regulated, more dangerous options while keeping safer, natural products illegal.
## PART FOUR: SUPPRESSED SCIENCE AND HISTORICAL PRECEDENTS
### 4.1 Documented Suppression of Cannabis Research
The history of cannabis research is marked by instances of promising findings being sidelined or suppressed:
**1974 National Cancer Institute Study:**
- Research demonstrated that THC shrank tumors in mice
- The study was not pursued further
- Funding was withdrawn
**1988 DEA Judge Ruling:**
- Administrative Law Judge Francis Young declared cannabis "one of the safest therapeutically active substances known to man"
- His ruling was subsequently overruled by the Reagan and Bush administrations
**Modern FOIA Records:**
- Freed documents confirm that federal officials were repeatedly made aware of the scientific evidence supporting the medical use of cannabis
- Information was withheld from the public
### 4.2 The Rick Simpson Oil (RSO) Case
In 2003, Canadian engineer **Rick Simpson** reported a personal recovery from skin cancer using a high-THC, full-spectrum cannabis oil. He became a prominent advocate for this natural medicine, widely known as RSO, which has since been anecdotally linked to improvements in cases of cancer, epilepsy, and chronic pain.
**Key Points:**
- Simpson faced significant legal persecution in Canada
- He eventually relocated to Uruguay—the first nation to legalize cannabis (2013)
- Critics argue that U.S. Patent 6,630,507 prioritized non-psychoactive cannabinoids like CBD, thereby sidelining THC-based therapies like RSO in favor of pharmaceutical derivatives such as Epidiolex
**Supporting Research:**
- *Cancers Journal* (2021) – THC and CBD have demonstrated tumor-shrinking effects in animal models
## PART FIVE: THE ENDOCANNABINOID SYSTEM (ECS)
### 5.1 A Biological Foundation
Discovered in the 1990s, the endocannabinoid system (ECS) is a fundamental biological regulator responsible for maintaining homeostasis across multiple physiological systems, including pain perception, inflammation, mood, memory, and neuroprotection. The ECS is comprised of endogenous cannabinoids, their receptors (CB1 and CB2), and the enzymes that synthesize and degrade them.
**Key Functions:**
- Pain perception
- Inflammation regulation
- Mood and emotion
- Memory and cognition
- Neuroprotection
- Appetite and metabolism
- Immune function
### 5.2 Phytocannabinoids and the ECS
Phytocannabinoids—such as THC, CBD, and CBG—interact with this system, modulating its activity to achieve therapeutic effects. This pharmacological relationship underpins the potential of cannabis to treat a wide array of chronic conditions.
**Research Support:**
- *Frontiers in Immunology* (2018) – ECS activation is involved in reducing inflammation, a factor in autoimmune disease
- *Journal of Neuroimmune Pharmacology* (2020) – Cannabinoids show neuroprotective properties in laboratory studies
### 5.3 Therapeutic Potential
**Alzheimer's Disease:**
- Research indicates that cannabinoids may help reduce agitation, aggression, and cognitive impairments in Alzheimer's and dementia patients
- U.S. Patent 6,630,507 specifically affirms cannabinoids' role as antioxidants and neuroprotectants with application in neurodegenerative diseases like Alzheimer's
- Multiple studies and clinical observations have shown improvements in cognitive and behavioral symptoms after cannabinoid treatment
**Addiction Recovery:**
- CBD has demonstrated benefits in aiding recovery from substance dependencies, including opioid, cocaine, tobacco, and alcohol addictions
- Research shows CBD may target relapse triggers such as anxiety, impaired impulse control, and environmental cues
- Evidence supports CBD's potential efficacy across multiple substance classes
## PART SIX: PERSONAL TESTIMONY — A DOCUMENTED HEALING
### 6.1 Medical Documentation (Documented Recovery) URL https://chat.deepseek.com/share/83gqxyah21lk5fo04p
The author of this document has personally experienced the healing potential recognized by U.S. Patent 6,630,507.
**Medical Record Summary:**
- **2017:** Diagnosis of Alzheimer's Disease (ICD-10: G30.9) by Dr. Sayed Monis, MD and Dr. Donald D. Vaughn, MD
- **12/05/2019:** Dr. Shiva Natarajan, MD (Neurologist) documented: "Patient currently has no neurological issues"
- **10/29/2020:** Dr. Suzette A. Kelly, MD recorded in the problem list: "Alzheimers disease... RESOLVED"
**Treatment:**
- No pharmaceutical medications since 2017/2018
- Therapeutic use of cannabis as the primary treatment
- Lifestyle changes and faith-based healing practices
**Current Status:**
- Sustained cognitive function for over five years
- No recurrence of symptoms
- Continued improvement in health
### 6.2 Faith Perspective
- *Genesis 1:29* – "Every herb bearing seed... to you it shall be for meat."
- *Psalm 104:14* – "He causeth the grass to grow for the cattle, and herb for the service of man."
- *Luke 8:17* – "For nothing is secret, that shall not be made manifest."
Scripturally, God's creation provides natural resources for healing and restoration. The documented pharmacological properties of cannabinoids can be viewed as consistent with the concept of divine provision embedded in creation. Biblical references are presented here as spiritual foundation, not as clinical evidence.
**Individual results vary. All medical decisions should involve qualified professionals.**
## PART SEVEN: PATTERNS OF SUPPRESSION
### 7.1 Documented Harassment and Targeting
The author has experienced a pattern of harassment and targeting consistent with documented suppression of natural medicine advocates:
**Identity Theft:**
- Fraudulent California Prop 215 recommendation created in the author's name
- Document used to facilitate illegal activity in another state
**Entrapment:**
- Induced to have cannabis shipped to Tennessee through deceptive means
- Individuals representing themselves as affiliated with Americans for Safe Access (ASA) were involved
**Prosecution:**
- Legal action for producing RSO (Rick Simpson Oil) for personal use and caregiving
- Court proceedings while caring for a mother with cancer
**Digital Suppression:**
- Website tampering
- Account interference
- Content alteration by unauthorized parties
- Ongoing cyberattacks targeting all digital assets
### 7.2 The ASA Incident
The author was contacted by individuals representing themselves as affiliated with **Americans for Safe Access (ASA)** , or persons impersonating that organization, in connection with this documentation.
**The Pattern:**
- Vulnerable individual (chronic illness, caregiver)
- Enticed or induced into illegal activity
- Prosecuted while others escape accountability
- Used as an example/warning to others
**Clarification:** The author is not presently asserting that ASA or any specific organization committed a crime. Rather, the materials are being preserved for independent examination of the evidence, including whether any government agency, third-party actor, or bad-faith entity was involved in the creation, distribution, or targeting of these documents.
### 7.3 Patterns of Suppression
Between 1956 and 1971, COINTELPRO was used to infiltrate and silence voices of dissent through surveillance, disinformation, harassment, and sabotage. Advocates compare modern treatment of cannabis and natural medicine advocates to these historical patterns, citing tactics including: COINTELPRO 2.0 Democracy Now
1. Covert Infiltration – Deploying undercover agents or informants to penetrate organizations, create internal divisions, provoke conflict, and sabotage operations from within. This tactic fractures trust, fosters paranoia, and undermines organizational cohesion.
2. Disinformation Campaigns – Orchestrating the deliberate spread of false or misleading information to undermine the credibility, messaging, and public trust of targeted individuals and groups. Disinformation sows confusion, isolates supporters, and distorts public perception.
3. Character Assassination – Publishing false reports, planting rumors, and engaging in public smear campaigns to destroy the reputations of leaders and activists. This tactic neutralizes effective voices by rendering them toxic or untrustworthy in the public eye.
4. Surveillance and Intelligence Gathering – Conducting extensive monitoring, wiretapping, and physical surveillance of political groups, civil rights leaders, and activists to collect intelligence on plans, strategies, and personal vulnerabilities.
5. Legal and Political Pressure – Supporting or initiating arrests, prosecutions, civil lawsuits, and administrative actions to obstruct activism, drain organizational resources, and create a chilling effect on participation.
6. Direct Interference with Activities – Sabotaging protests, meetings, organizational functions, and public events to weaken, disrupt, or dismantle targeted groups and neutralize their effectiveness.
7. Harassment and Intimidation – Employing tactics such as repeated phone harassment, mail interference, unwarranted visits, and personal intimidation to suppress active participation and create a pervasive climate of fear.
8. Strategic Intelligence Collection – Gathering covert intelligence on planned political activities, upcoming actions, and strategic moves to anticipate and counter activist efforts before they gain traction.
9. Public Discrediting – Systematically undermining public trust in activist organizations through targeted smear campaigns, media manipulation, and reputational attacks designed to isolate groups from their supporters.
10. Provocateur Placement – Planting agent provocateurs within groups to instigate conflict, provoke rash or violent actions, and fracture internal cohesion, thereby providing justification for legal or public backlash.
11. Legal Attrition Warfare – Hindering organizational effectiveness by entangling activists in costly, time-consuming legal battles, frivolous lawsuits, and repetitive law enforcement actions that drain financial and emotional resources.
12. Preemptive Counterintelligence – Using continuous monitoring and threat assessment to anticipate and neutralize the moves of civil rights leaders and organizers before they can build momentum or achieve strategic objectives.
13. Neutralization of Peaceful Assembly – Interfering with lawful protests, public meetings, and organized gatherings through permits denial, surveillance, infiltration, or direct disruption to dilute their impact and render them ineffective.
14. Direct Personal Harassment – Subjecting targeted individuals to sustained personal harassment—including threats, stalking, social media attacks, and workplace interference—to foster an environment of intimidation and psychological pressure.
15. Infrastructure Sabotage – Weakening the overall infrastructure of political movements through repeated disruption, resource depletion, financial targeting, and organizational destabilization, making sustained activism unsustainable.
**Clarification on Historical Comparison:** These comparisons are intended as contextual and structural observations, highlighting recognizable patterns—such as censorship, intimidation, and disruption of lawful advocacy—documented both historically and in modern public records. Readers are encouraged to examine the historical records directly. Citizens' Commission to Investigate the FBI: 1971
## PART EIGHT: CONCLUSION — A MANDATE FOR REFORM
### 8.1 The Evidence Is Unequivocal
The U.S. patent system, federal research funding, and the deployment of FDA-approved cannabinoid pharmaceuticals demonstrate a formal, long-standing acknowledgment of cannabis's therapeutic value. Yet, the plant itself remains in the most restrictive category of the Controlled Substances Act.
**The Contradiction:**
- **67 patents** spanning 8 decades → Schedule I classification
- **HHS patent** for neuroprotection → "No accepted medical use"
- **4 FDA-approved** cannabinoid drugs → Whole plant remains illegal
- **Endocannabinoid System** discovered → Natural ligands remain prohibited
- **Thousands of research studies** → Research severely restricted
### 8.2 The Cost of This Policy
This paradox is no longer tenable. The continuation of this policy is not only a scientific fallacy but also a profound injustice:
- **Patients** are denied access to a plant-based medicine with proven applications
- **Prisoners** languish in cells for using what the government itself patents
- **Research** is stifled, delaying potential cures
- **Science** is subordinated to ideology and commercial interests
### 8.3 A Call for Reform
The record demands a reevaluation of cannabis policy, placing evidence, human testimony, and historical fact above ideology and commercial interests.
**What Is Needed:**
- **Rescheduling** — Remove cannabis from Schedule I
- **Research** — Fund comprehensive clinical studies
- **Access** — Ensure patient access to whole-plant medicine
- **Justice** — Release nonviolent cannabis prisoners
- **Truth** — Acknowledge the historical suppression
## APPENDIX A: SOURCES AND FURTHER READING
### Patents and Legal Documents
- U.S. Patent and Trademark Office – Patent Center
- Google Patents – patents.google.com
- Lens.org Patent Records – lens.org
- U.S. Patent 6,630,507 — Cannabinoids as antioxidants and neuroprotectants
### Research and News
- Denver Post – "Patent No. 6,630,507: Why the U.S. government holds a patent on cannabis plant compounds"
- Kannalife Sciences License Agreement – kannalife.com
- PMC – Trends in intellectual property rights protection for medical cannabis
- FiercePharma – FDA approval of Epidiolex
- CNBC – Jazz Pharmaceuticals $7.2B acquisition of GW Pharma
- NIH StatPearls – Dronabinol
- FDA – Marinol (Dronabinol) Label
- Sterne Kessler – Cannabis Patent Activity Surges
### Scripture References
- Genesis 1:29 – "Every herb bearing seed... to you it shall be for meat"
- Psalm 104:14 – "He causeth the grass to grow for the cattle, and herb for the service of man"
- Luke 8:17 – "For nothing is secret, that shall not be made manifest"
## APPENDIX B: SECURITY NOTICE
**IMPORTANT:** This document is being published amidst ongoing cyberattacks targeting our website, social media accounts, and digital assets. Unauthorized actors have accessed, interfered with, and manipulated our content.
**Official Channels:**
- Website (Main): https://www.bfreedindeed.net/
- Patent Reference: https://www.bfreedindeed.net/united-states-patent-us6630507b1
**Note:** Readers are encouraged to verify all claims through primary sources. This document is for research and educational purposes only. It is not medical advice. | The Reason Cannabis was Prohibited
"For nothing is secret, that shall not be made manifest; neither any thing hid, that shall not be known and come abroad." — Luke 8:17
**Soli Deo Gloria** Glory to God alone
━━━━━━━━━━━━━━━━
🔥 Kaneh-Bosem: The Lost Cannabis of Scripture – A Restored Truth
## A Synthesis of Linguistic, Archaeological, and Theological Research
This study challenges traditional translations of the Hebrew term **kaneh-bosem** (קָנֶה־בֹּשֶׂם) and presents evidence for its identification as cannabis. This is not speculation—it is evidence-based restoration drawing from linguistics, archaeology, and biblical textual analysis.
## Page 1: The Forgotten Name – Kaneh-Bosem
### The Term
The Hebrew term **kaneh-bosem** is consistently translated in modern Bibles as "calamus" or "sweet cane." A closer examination reveals this may be a profound mistranslation that obscured the original plant's identity.
### The Linguistic Evidence
- **Etymological Connection**: Hebrew *kaneh* (reed, stalk) is linguistically linked to ancient cognates:
- **Sanskrit**: *śana*
- **Assyrian**: *qunnabu*
- **Persian**: *kenab*
- **Arabic**: *kanab*
- **The Septuagint Translation Error**: The Greek Septuagint (3rd century BCE) translated *kaneh-bosem* as "sweet *kalamos*" (calamus), obscuring the original plant identification. This translation was repeated in subsequent versions including Martin Luther's Bible
- **Double Meaning of "Kan"**: In many ancient languages, including Hebrew, the root "kan" carried a double meaning—both "hemp" and "reed"—suggesting the original term was more specific than later translators recognized
- **Sula Benet's Research**: Polish anthropologist Sula Benet (1903–1982) first proposed this identification in 1936 at a Warsaw seminar. She argued that the mistranslation originated with the Septuagint and was perpetuated through centuries of biblical translation
### The Archaeological "Smoking Gun"
- **The Tel Arad Discovery (2020)**: A groundbreaking study published in *Tel Aviv: Journal of the Institute of Archaeology* revealed that limestone altars from the 8th-century BCE Judahite shrine at Tel Arad contained residues of **THC, CBD, and CBN**—the psychoactive compounds of cannabis
- **Date and Context**: The shrine was in use from approximately **760 to 715 BCE** within the Kingdom of Judah. The fortress at Tel Arad guarded Judah's southern border, about 45 kilometers west of the Dead Sea
- **Deliberate Psychoactive Use**: The cannabis was mixed with animal dung to enable low-temperature burning, allowing ritual specialists to inhale the mind-altering fumes. The researchers concluded: *"It seems feasible to suggest that the use of cannabis on the Arad altar had a deliberate psychoactive role. The smells of cannabis are not attractive and do not justify bringing them from afar"*
- **First Evidence in the Region**: This represents the earliest known evidence of cannabis use in the Ancient Near East. *"Arad provides the earliest evidence for the use of cannabis in the Ancient Near East. Hallucinogenic substances are known from various neighboring cultures, but this is the first known evidence of hallucinogenic substance found in the Kingdom of Judah"*
### Why Was This Knowledge Hidden?
1. **Hellenistic Bias**: Greek translators of the Septuagint, unfamiliar with the original Canaanite plant use, substituted the known Greek reed *kalamos*
2. **Cultural and Theological Shifts**: Later church doctrine and modern prohibitionist narratives systematically obscured this history, reframing a sacred plant as solely a substance of abuse
3. **Linguistic Conservatism**: Once a mistranslation entered the textual tradition, it was perpetuated through centuries of biblical transmission
### Scholarly Context
Sula Benet's claim has found some support in the academic community, with standard reference lexicons of Biblical Hebrew and reference works on Hebrew Bible plants by scholars like Jerusalem botanist Michael Zohary mentioning her suggestion. However, others argue the word refers to a different species of hemp or a different plant entirely—including sweet flag (*Acorus calamus*), *Andropogon calamus*, *Arundo donax L.*, or sugarcane
## Page 2: Calamus vs. Cannabis – A Botanical and Theological Reckoning
### The Case Against Calamus
The argument for "calamus" (sweet flag, Acorus calamus) as the correct translation faces significant botanical and practical challenges:
Height
-
Cannabis (Cannabis sativa): Grows 12–20+ feet—a true, towering reed
-
Calamus (Acorus calamus): Reaches only 1–3.5 feet maximum
Toxicity & Safety
-
Cannabis: Non-toxic; historically used as a medicinal plant
-
Calamus: Contains β-asarone, a known carcinogen banned by the FDA in food products
Archaeological Evidence
-
Cannabis: Confirmed at the Tel Arad altar site, dating to 760–715 BCE
-
Calamus: No archaeological evidence connecting it to ancient Israelite ritual contexts
Fragrance Profile
-
Cannabis: Possesses a potent, distinctive aroma—fitting the Hebrew term bosem ("fragrant")
-
Calamus: Produces only a mild, sweet scent—less distinctive and less suitable for sacred anointing oil
Practical Usability
-
Cannabis: Sturdy, versatile, and suitable for anointing oil and ritual applications
-
Calamus: Small and impractical for the ritual uses described in Scripture
Summary
The evidence strongly suggests that calamus was a later, incorrect substitution that entered the textual tradition through the Septuagint translation, obscuring the original plant—cannabis—that was actually used in ancient Israelite worship.
### Theological Implication
- **Genesis 1:29** states God gave "every seed-bearing plant... for food." Cannabis fits as a safe, useful creation
- Recommending a carcinogenic calamus for holy anointing oil contradicts the nature of a benevolent God's gifts
- The evidence suggests calamus was a later, incorrect substitution that entered the textual tradition through the Septuagint translation
### The Tel Arad Confirmation
The 2020 discovery confirms cannabis was present and used in Judahite ritual contexts:
- **On the smaller altar**: Cannabis mixed with animal dung, burned at low temperature for psychoactive effect
- **On the larger altar**: Frankincense (*boswellic acid*) mixed with animal fats for higher-temperature burning
The researchers noted that because cannabis fragrance does not lend itself to use as incense, it was almost certainly burned for its drug properties—*"to stimulate ecstasy as part of cultic ceremonies"*
## Page 3: The Measuring Reed – Restoring Practicality to Ezekiel's Vision
### The Text
In Ezekiel 40:3-5, a "man with a measuring reed (*kaneh*) of six cubits" (approximately 9–11 feet) is used to blueprint the future Temple.
### The Calamus Problem
A 1–3.5 foot calamus stalk is physically impossible as a measuring tool of this length. This creates a significant practical inconsistency in the traditional interpretation
### The Cannabis Solution
A mature, sturdy, hollow cannabis stalk (16–20 feet) is perfect for crafting a long, straight measuring rod:
- Provides the necessary length for a six-cubit measuring tool
- Sturdy enough for repeated use in construction
- Hollow structure suitable for a lightweight measuring instrument
### Why This Matters
- **Restores Textual Accuracy**: Identifies a practical, usable plant for the measuring rod in Ezekiel's vision
- **Connects to Material Culture**: Demonstrates ancient Israel's practical engagement with hemp as an agricultural and industrial resource
- **Strengthens the Kaneh-Bosem Identification**: A single plant type—cannabis/hemp—appears across multiple biblical contexts
## Page 4: Hyssop or Hemp? The Crucifixion Reed Mystery
### The Text
John 19:29 states: *"A jar of wine vinegar was there, so they soaked a sponge in it, put the sponge on a stalk of the hyssop plant, and lifted it to Jesus' lips"* (NIV)
### The Botanical Problem
- **Hyssop is a small, bushy herb** (1.5–2 feet tall)
- **A crucified man's head** would be far beyond the reach of a hyssop stalk
- This presents a significant practical inconsistency in the traditional interpretation
### The Linguistic Clue
- The Greek word used is **κάλαμος** (*kalamos*)—the same word used in the Septuagint for *kaneh*
- This is best translated as "reed," not specifically "hyssop"
- Mark's Gospel specifically mentions a "reed" (*kalamos*) being used (Mark 15:36)
### A Plausible Resolution
- The text may record a **strong, long reed** (possibly a cannabis stalk) being used to lift the sponge
- The Gospel writer may have **symbolically connected** this act to the Passover hyssop (Exodus 12:22) for theological depth, while describing the practical object used
- This demonstrates how theological symbolism and practical description can coexist in the Gospel accounts
### Archaeological Context
- The Tel Arad find confirms cannabis was present and used in Judahite ritual contexts for centuries (8th century BCE)
- This makes its presence in 1st-century Judea not only plausible but likely
## Page 5: The Prophetic "Smoking Flax" – Isaiah 42:3 Fulfilled
### The Text
*"He will not break a bruised reed, and he will not extinguish a smoking flax..."* (Isaiah 42:3, WEB)
### Temple Context
- The **"smoking flax"** (or smoldering wick) directly evokes the incense altar
- The sacred incense, according to Exodus 30, included *kaneh-bosem*
- This creates a connection between the prophetic imagery and the actual Temple practice
### Messianic Fulfillment
- This prophecy is applied to Jesus in Matthew 12:20
- He comes **not to extinguish** the faint, smoldering flame of true worship and healing
- The sacred, smoky incense of *kaneh-bosem* symbolizes this divine presence
- The restoration of sacred plant knowledge becomes part of Christ's redemptive work
### The Grand Unification
The evidence converges to reveal a **single plant** woven through Scripture for sacred purposes:
1. **Anointing Oil**: *Kaneh-bosem* was a primary ingredient in the Holy Anointing Oil (Exodus 30:23), used to consecrate priests, prophets, and kings
2. **Holy Incense**: It was likely a component of the sacred temple incense, creating the "cloud over the mercy seat" (Leviticus 16:12-13)
3. **Architectural Tool**: Its stalk served as the practical measuring reed for God's temple blueprint (Ezekiel 40:3-5)
4. **Crucifixion Instrument**: Its form may have been the reed that served Christ in His final moments (John 19:29, Mark 15:36)
## Why This Restoration Matters
### Theological Integrity
- Corrects a centuries-old mistranslation
- Aligns God's creation with His benevolent intent (Genesis 1:29, 1 Timothy 4:4)
- Reveals the consistency of God's provision across Scripture
### Historical Honesty
- Integrates definitive archaeological science with textual study
- The Tel Arad finding (2020) provides physical proof of cannabis in Judahite ritual
- Demonstrates the importance of modern scientific methods for biblical interpretation
### Prophetic Fulfillment
- Sees the restoration of this knowledge as part of the "crooked things made straight" promised in Isaiah 40:4
- Fulfilled in Christ's ministry and continuing work of restoration
- The "smoking flax" of true worship is rekindled, not extinguished
## Important Biblical Warning
### Exodus 30:33
> *"Whosoever compoundeth any like it, or whosoever putteth any of it upon a stranger, shall even be cut off from his people"*
### Key Distinctions
1. This study explores **historical and biblical contexts** only
2. It does **not authorize recreating** the Exodus 30 formula
3. **Respectful therapeutic use** of biblical plants for personal wellness is permitted
4. **Replicating the exact formula** reserved for Tabernacle worship is forbidden
## Final Call to Action
### This research must be preserved and shared. It challenges:
- **Seminaries** to re-examine their lexicons and historical assumptions
- **Historians** to integrate the Tel Arad findings into mainstream scholarship
- **Believers** to prayerfully reconsider the role of God's creation in healing and worship
- **Society** to distinguish between sacred use and abuse, ending the stigma against a plant once deemed holy
### The truth is ancient, fragrant, and has been waiting to be rediscovered.
## Further Reading and Sources
- Benet, Sula (1936). *Early Diffusions and Folk Uses of Hemp*
- Bennett, Chris. *Cannabis and the Soma Solution* (2010)
- Arie, Eran et al. (2020). "Cannabis on the Altar of Tel Arad." *Tel Aviv: Journal of the Institute of Archaeology*
- Russo, Ethan. *Handbook of Cannabis Therapeutics* (2011)
## Disclaimer
This study focuses on **ancient historical and linguistic contexts** and does not advocate for modern recreational cannabis use. The spiritual and medicinal use of cannabis today remains a matter of personal conscience and should be approached with wisdom, legality, and respect for biblical boundaries (Exodus 30:33). (KANEH-BOSEM Page has Expanded Studies, click here) 🕵️
**"Prove all things; hold fast that which is good." — 1 Thessalonians 5:21**
